Lord, Abbett & Co
ADPT icon

Lord, Abbett & Co’s Adaptive Biotechnologies ADPT Stock Holding History

Lord, Abbett & Co’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.1M Sell
2,474,814
-1,061,289
-30% -$16.3M 0.15% 170
2026
Q1 		$49.1M Buy
3,536,103
+455,344
+15% +$7.25M 0.16% 164
2025
Q4 		$50M Buy
3,080,759
+1,854,355
+151% +$30.3M 0.15% 167
2025
Q3 		$18.3M Buy
1,226,404
+29,509
+2% +$360K 0.05% 301
2025
Q2 		$13.9M Buy
1,196,895
+169,628
+17% +$1.54M 0.04% 341
2025
Q1 		$7.63M Buy
+1,027,267
New +$7.9M 0.03% 412
2021
Q1 		– Sell
-656,031
Closed -$38.8M – 631
2020
Q4 		$38.8M Buy
656,031
+202,890
+45% +$10.5M 0.1% 302
2020
Q3 		$22M Buy
+453,141
New +$19M 0.07% 361
2019
Q3 		– Sell
-255,906
Closed -$12.4M – 698
2019
Q2 		$12.4M Buy
+255,906
New +$11.3M 0.04% 515

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lord, Abbett & Co's ADPT Position: Q2 2026 in Review

Lord, Abbett & Co reduced its Adaptive Biotechnologies (ADPT) stake by 30% in Q2 2026, selling an estimated $16.3M and leaving 2,474,814 shares worth $53.1M. The position accounts for 0.15% of the portfolio, ranked #170.

Lord, Abbett & Co first reported a position in ADPT in Q2 2019 and has held it in 9 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Lord, Abbett & Co held 2,474,814 shares of Adaptive Biotechnologies worth $53.1M as of Q2 2026.
  • Lord, Abbett & Co sold 1,061,289 Adaptive Biotechnologies shares in Q2 2026, an estimated $16.3M.
  • Adaptive Biotechnologies made up 0.15% of Lord, Abbett & Co's portfolio in Q2 2026, its #170 holding.
  • Lord, Abbett & Co first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 9 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.